U.S., Feb. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07418736) titled 'A Phase II Study of CM326 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease' on Feb. 04.
Brief Summary: This study is a multi-center, randomized, double-blind, placebo-controlled Phase II clinical study to evaluate the efficacy, safety, PK characteristics, PD effects and immunogenicity of CM326 in subjects with moderate to Severe Chronic Obstructive Pulmonary Disease.
The study consists of a screening period of up to 4 weeks, a randomized treatment period of 24 to 52 weeks, and a 12-week safety follow-up period.
Study Start Date: Dec. 18, 2025
Study Type: INTERVENTIONAL
Condition:
Chronic Obstructive Pul...